Thus, restoring TFAP4 expression in c-MYC driven blood cancers, might ameliorate disease progression, not by killing the tumour cells, but by inducing normal differentiation of the self-renewing pre-B lymphoma cell pool into less proliferative immature/mature B cells, albeit only if these cells are dependent on sustained absence of TFAP4 for lymphoma maintenance and not only for lymphoma development. This evidence concerns the gene TFAP4 and hematopoietic and lymphoid system neoplasm.